This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Parkinson's disease (PD); Huntington's disease (HD)	Sirtuin 2 (SIRT2)	<p>A SAR study identified SIRT2 inhibitors that could be useful for treating PD and HD. Screening of a 2-anilinobenzamide compound library identified two leads that inhibited SIRT2 <i>in vitro</i> and in cell culture more potently and selectively than a previously reported reference compound. Next steps include evaluating the lead compounds in animal models. Indus Biotech Pte. Ltd. has the SIRT2 inhibitors INDUS815B and INDUS815C in preclinical development for PD and HD, respectively. Elixir Pharmaceuticals Inc. and Siena Biotech S.p.A. have EX-527, an inhibitor of the related enzyme SIRT1, in Phase I testing for HD.</p> <p>SciBX 5(26); doi:10.1038/scibx.2012.684 Published online June 28, 2012</p>	Unpatented; licensing status not applicable	<p>Suzuki, T. <i>et al. J. Med. Chem.</i>; published online May 29, 2012; doi:10.1021/jm3002108 Contact: Naoki Miyata, Nagoya City University, Aichi, Japan e-mail: miyata-n@phar.nagoya-cu.ac.jp Contact: Takayoshi Suzuki, Kyoto Prefectural University of Medicine, Kyoto, Japan e-mail: suzukit@koto.kpu-m.ac.jp</p>